Your search for esrd returned 10 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove
Post remove
MPR First Report remove

Your search for esrd returned 10 results

Sort Results:

Relevant Recent
ACR/ARHP Annual Meeting 2015

Is Non-TNF Targeted Tx Better Than a Second Anti-TNF Drug?

A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.
ACR/ARHP Annual Meeting 2015

Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA

Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
ACR/ARHP Annual Meeting 2015

Long-term Etanercept Boasts Better Retention Rates than Adalimumab in RA

Long-term etanercept is associated with modestly better treatment retention rates than adalimumab among patients with rheumatoid arthritis (RA), according to an analysis of data from the RHUMADATA® clinical registry and database presented at the 2015 ACR/ARHP Annual Meeting.
American College of Cardiology 2011

Lipid Management in Special Populations

Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.